Navigation Links
New Data Shows AZOR(R) (amlodipine and olmesartan medoxomil) Significantly Improves 24-Hour Ambulatory Blood Pressure
Date:5/8/2009

e rate of high blood pressure is disproportionately high in the Black community and affects 41 percent of the population.(9) A further analysis of the AZTEC trial on the basis of race found that treatment with an amlodipine and olmesartan medoxomil-based titration regimen was well tolerated and produced similar 24-hour ambulatory BP reductions from baseline in both Black and non-Black patients. Black patients had a higher mean baseline BP than non-Black patients. The amlodipine and olmesartan medoxomil-based titration regimen produced mean 24-hour ambulatory BP reductions of 20.7/11 mm Hg in Black patients from a baseline of 148.6/85.7 mm Hg. Non-Black patients experienced a mean 24-hour ambulatory BP reduction of 21.5/13 mm Hg from a baseline of 144.2/85.7 mm Hg.

Patients with Diabetes

Seventy five percent of adults diagnosed with diabetes in the U.S. have hypertension.(10),(11) A further analysis of the AZTEC trial found that treatment with an amlodipine and olmesartan medoxomil-based titration regimen was well tolerated and produced similar 24-hour ambulatory BP reductions from baseline in hypertensive patients with and without diabetes. Patients with diabetes treated with the amlodipine and olmesartan medoxomil-based titration regimen also achieved mean 24-hour ambulatory BP reductions of 21.5/12.6 mm Hg from a baseline of 145.6/83.1 mm Hg. Patients without diabetes experienced a mean 24-hour ambulatory BP reduction of 21.3/12.8 mm Hg from a baseline of 144.6/86.6 mm Hg.

Study Design

AZTEC was a 15-16-week (3- to 4-week placebo run-in and 12-week active treatment periods), open label, prospective, single-arm, titrate-to-goal study, conducted in 185 patients with mild to moderate (Stage 1) and challenging (Stage 2) hypertension. The study evaluated the safety and efficacy of an amlodipine and olmesartan medoxomil-based titration algorithm. Of the total study population, 26 patients were Black
'/>"/>

SOURCE Daiichi Sankyo, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
2. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
3. Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
4. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
5. Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
6. Cleveland Clinic Study Shows the Diabetes Drug Pioglitazone Reduces Risk of Death, Heart Attack and Stroke, but Increases Risk of Heart Failure
7. New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
8. Feeling Anxious or Distracted? New Research Shows a Cup of Tea Could Help
9. New Study Shows Once-Monthly Boniva(R) is as Clinically Effective as Once-Weekly Fosamax(R) at Increasing Bone Mineral Density in Postmenopausal Women With Osteoporosis
10. Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia
11. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 2014   Decision Resources Group finds that ... chronic kidney disease non-dialysis (CKD-ND) patients are not ... In addition, one-year persistency is similar between Amgen,s ... key findings from the report entitled ... Stimulating Agents in Late Stage Chronic Kidney Disease ...
(Date:9/30/2014)... Ind. , Sept. 30, 2014  The orthopedic specialists ... the nation,s No. 6 orthopedic group by US News ... Active Adults," a series of free, public seminars to ... all over the world come to see the knee ... procedures are now available at Munster Specialty Surgery Center. ...
(Date:9/30/2014)... In 2011, approximately 5.1 million people in ... pain relievers (e.g. opioids). 1 Clinical treatments for ... the use of buprenorphine, buprenorphine/naloxone, naltrexone or methadone. The ... developing and improving care management programs, according to ... Therapeutics LLC (Prime). Cost trends ...
Breaking Medicine Technology:Persistency is Low for Late-Stage Anemic CKD Non-Dialysis Patients Treated with Erythropoiesis-Stimulating Agents 2Persistency is Low for Late-Stage Anemic CKD Non-Dialysis Patients Treated with Erythropoiesis-Stimulating Agents 3"Knee Pain Solutions for Active Adults" Complimentary Seminars Open to the Public 2Studies show cost and use of opioid dependence treatment are increasing, spurring the need for care management programs 2Studies show cost and use of opioid dependence treatment are increasing, spurring the need for care management programs 3
... UCB) and U.S. based partner Immunomedics Inc. (Nasdaq: ... IIb study, EMBLEM™, showed that certain doses of epratuzumab ... in disease activity in adult patients with moderate to ... designed to evaluate the efficacy and safety of epratuzumab ...
... innovator of Packaging Execution Systems (PES) for the pharmaceutical ... engineering, automation and manufacturing optimization services company, today announced ... Service Provider (SSP). VCG will now sell, install and ... United States. The SSP program is ...
Cached Medicine Technology:Epratuzumab Phase IIb Data Presented at ACR Show Pipeline Drug had Positive Effect in Patients Suffering From Moderate to Severe Systemic Lupus Erythematosus 2Epratuzumab Phase IIb Data Presented at ACR Show Pipeline Drug had Positive Effect in Patients Suffering From Moderate to Severe Systemic Lupus Erythematosus 3Epratuzumab Phase IIb Data Presented at ACR Show Pipeline Drug had Positive Effect in Patients Suffering From Moderate to Severe Systemic Lupus Erythematosus 4Epratuzumab Phase IIb Data Presented at ACR Show Pipeline Drug had Positive Effect in Patients Suffering From Moderate to Severe Systemic Lupus Erythematosus 5Epratuzumab Phase IIb Data Presented at ACR Show Pipeline Drug had Positive Effect in Patients Suffering From Moderate to Severe Systemic Lupus Erythematosus 6Epratuzumab Phase IIb Data Presented at ACR Show Pipeline Drug had Positive Effect in Patients Suffering From Moderate to Severe Systemic Lupus Erythematosus 7Systech International and Vantage Consulting Group Partner to Address Emerging U.S. Pharmaceutical Regulatory Requirements 2Systech International and Vantage Consulting Group Partner to Address Emerging U.S. Pharmaceutical Regulatory Requirements 3
(Date:9/30/2014)... Health Day Reporter TUESDAY, ... who are overweight or obese when diagnosed appear to ... weight-related cancer, new research suggests. , , The finding ... only the potential for developing other cancers associated with ... who reported being overweight or obese prior to diagnosis ...
(Date:9/30/2014)... Symposia will convene the first conference of its 2014-2015 ... Series on "The Modes of Action of Vaccine ... the conclusion of the Grand Challenges Meeting for that ... Keystone Symposia Global Health Series, supported by the Bill ... awards for 36 investigators from developing countries to attend. ...
(Date:9/30/2014)... Integrated Medicine Alliance , Monmouth County’s ... medical specialty practice through a unique partnership with an ... located within the company’s Shrewsbury location and will be ... of American Heart Center, P.C., a highly regarded practice ... Integrated Medicine Alliance patients top notch cardiovascular care without ...
(Date:9/30/2014)... team has been awarded a three-year $1.7 million ... to develop new imaging technologies and data analysis ... large networks of neurons in the brain interact ... researchers identify the precise interactions between millions of ... speaking, and alterations in these interactions that may ...
(Date:9/30/2014)... Vegas, NV (PRWEB) September 30, 2014 ... is helping people perform better in and out of the ... and memory has caught the attention of Shane Michaels, prompting ... day-to-day grind, fatigue is the reason most people simply just ... whether that means staying focused at work, getting the motivation ...
Breaking Medicine News(10 mins):Health News:Obesity Tied to Higher Cancer Risk for Colon Cancer Survivors 2Health News:Obesity Tied to Higher Cancer Risk for Colon Cancer Survivors 3Health News:Keystone Symposia launches 2014-2015 meeting series with Global Health Vaccines Conference 2Health News:Integrated Medicine Alliance Announces New Cardiology Practice 2Health News:UMD receives inaugural BRAIN Initiative Award 2Health News:Elevate: Review Exposes Blue Star Nutraceutical’s Latest Supplement for Ultimate Brain Function, Focus, and Energy 2
... released software program will let health authorities at the ... speeding the detection of new cases and the implementation ... was developed by a team of epidemiologists and computer ... (MIDAS), an international program supported by the National Institutes ...
... Cover Election, Customer Service and Other Work Life Topics ... That Counter Recent ... those,surveyed in the 2007 Annual Work+Life Fit Reality Check believe the ... offer and individuals to have more work life flexibility.,The telephone survey ...
... Avani to Represent Dermatology Products Featuring Invisicare(R), ... Inc. (OTC,Bulletin Board: SKVI) / (Website: ... has signed a marketing agreement with Avani,International ... it was granted a comprehensive patent in ...
... Dec. 6 Insmed Inc. (Nasdaq:,INSM), a developer of ... at the IBC 5th Annual Global Follow-On Biologics,Conference on ... The conference, to be held at the Hyatt Regency ... through Tuesday, December,11th, and will bring together corporate, regulatory, ...
... Health, Inc. (Amex: OPK ),today reported that the ... of wet age-related macular degeneration (wet,AMD), was named one ... III,clinical trials during the third quarter of 2007. The ... to Watch report issued by Thomson,Scientific Inc. Thomson,s industry ...
... you get for the nut,that has everything, including more than ... talking therapy doll?, You can at once give a ... it, their own personal and portable psychotherapist. The,Ask Doctor Chuck ... could,earn you the undying gratitude of the rest of your ...
Cached Medicine News:Health News:New software to aid early detection of infectious disease outbreaks 2Health News:Employees Want the Next President's Agenda to Make Work Life Flexibility Easier for Companies and Individuals 2Health News:Employees Want the Next President's Agenda to Make Work Life Flexibility Easier for Companies and Individuals 3Health News:Employees Want the Next President's Agenda to Make Work Life Flexibility Easier for Companies and Individuals 4Health News:Employees Want the Next President's Agenda to Make Work Life Flexibility Easier for Companies and Individuals 5Health News:Skinvisible Signs Marketing Agreement for India 2Health News:Skinvisible Signs Marketing Agreement for India 3Health News:Insmed to Present at the IBC 5th Annual Global Follow-On Biologics Conference 2Health News:OPKO's Bevasiranib Named One of Most Promising Drugs Recently Entering Phase III Trials 2Health News:OPKO's Bevasiranib Named One of Most Promising Drugs Recently Entering Phase III Trials 3Health News:OPKO's Bevasiranib Named One of Most Promising Drugs Recently Entering Phase III Trials 4Health News:The Cure for Holiday Stress 2
The fat loss formula's key ingredient of 2.0% aminophylline works by penetrating deep into the skin where it causes the body fat cells to shrink, resulting in up to 2 inches of body fat loss....
... VelaSmooth is the first ... device with the revolutionary elos ... Radio Frequency and Infrared Light ... with suction to reduce the ...
... was designed with the physician, staff ... you the best economy exam room ... does not skimp on patient comfort. ... can easily position patients so that ...
The Salt A-Peel™ microdermabrasion combines, positive air pressure, pure salt, ultrasound and the application of rich anti oxidant products to deliver a remarkable 'The Salt A-Peel' anti ageing...
Medicine Products: